Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study

Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of pre...

Full description

Saved in:
Bibliographic Details
Published inMedical and pediatric oncology Vol. 19; no. 2; p. 126
Main Authors Stiff, P J, Sweet, D, Kilton, L J, Johnson, C M, Muntean, B, Blough, R R
Format Journal Article
LanguageEnglish
Published United States 1991
Subjects
Adult
Aged
Anthracenes - administration & dosage
Anthracenes - adverse effects
Anthracenes - therapeutic use
Antibiotics, Antineoplastic - administration & dosage
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - therapeutic use
Drug Administration Schedule
Drug Evaluation
Female
Humans
Illinois
Infusions, Intravenous
Leukopenia - chemically induced
Male
Melanoma - drug therapy
Melanoma - secondary
Middle Aged
Phlebitis - chemically induced
Survival Rate
Illinois
Online AccessGet more information

Cover

More Information
Summary:Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.
ISSN:0098-1532
DOI:10.1002/mpo.2950190211